Navigation Links
NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain
Date:10/28/2009

MAPLE GROVE, Minn., Oct. 28 /PRNewswire/ -- NeuroVasx, Inc., a medical device company that develops technologies for the treatment of hemorrhagic and ischemic stroke, announced today that the first procedure in Spain utilizing its cPAX Aneurysm Treatment System was performed in Madrid. cPAX received CE Mark earlier this year.

Dr. Alfredo Casasco, Interventional Neuroradiology, Department of Endovascular and Percutaneous Treatment, Clinica Nuestra Senora del Rosario, used 143cm of cPAX in combination with platinum coils to treat an unruptured aneurysm over 13mm in diameter.

"According to the AngioCalc aneurysm volume calculator, greater than 40% packing density was achieved with cPAX alone, which we see as a great result," said Kathryn Meintsma, Vice President of Marketing, NeuroVasx. "Studies have indicated that aneurysms packed greater than 24% have a lower incidence of recanalization."(1,2)

"We are very pleased with the outcome of the first procedure in Spain, which demonstrates the sophisticated filling capabilities of cPAX in large aneurysms," said Eric B. Timko, President and Chief Executive Officer, NeuroVasx. "cPAX was designed to simplify delivery, shorten procedure time and improve outcomes, and the product's polymer characteristics make it ideally suited to take on the shape of large aneurysms and attain maximized packing density. This case marks a significant milestone in our entry into the European market and we look forward to continuing to introduce cPAX throughout the EU."

The cPAX System is a minimally invasive device for the embolization of cerebral aneurysms, abnormal bulges or sacs in the wall of an artery in the brain. If ruptured, aneurysms can result in massive intracranial bleeding and often lead to death. cPAX is a polymer strand delivered through a microcatheter using the same delivery technique as the currently used platinum coil technology. cPAX was designed to achieve more complete filling of the aneurysm using fewer devices and provide the physician the ability to detach the device at any point versus the fixed detachment zone common to platinum coils. The polymeric material also allows for non-invasive CT and MRI scans free of metallic artifact for a more accurate patient follow-up assessment.

  1. Tamatani S, Ito Y, Abe H, et al: Evaluation of the stability of aneurysms after embolization using detachable coils: Correlation between stability of aneurysms and embolized volume of aneurysms. AJNR May 2002, 23:762-767.
  2. Sluzewski M, Willem JvR, Slob MJ, et al: Relation between aneurysm volume, packing, and compaction in 145 cerebral aneurysms treated with coils. Radiology 2004; 231:653-658.

About Cerebral Aneurysms

A cerebral aneurysm is an abnormal bulge or sac in the wall of an artery in the brain which can be caused by a number of factors including congenital defects, high blood pressure, atherosclerosis, cancer, drug use or head trauma. If a cerebral aneurysm ruptures, it can lead to a hemorrhagic stroke, or bleeding on the brain. According to National Institutes of Health, approximately 40% of these patients do not survive the first 24 hours. The worldwide incidence of cerebral aneurysms is estimated to be 320,000 annually, approximately 200,000 of which may be treatable with intracranial surgery or minimally invasive techniques.

About NeuroVasx, Inc.

NeuroVasx, Inc. (http://www.neurovasx.com/) is a privately held medical device company located in Maple Grove, MN. The company is dedicated to the development and commercialization of technologies for the minimally invasive treatment of hemorrhagic and ischemic stroke. The worldwide market potential for stroke treatment devices is estimated to be over $3 billion.

    Contact:                                    Media Contacts:
    Eric B. Timko                               Jennifer Saunders
    President and CEO                           The Ruth Group
    NeuroVasx                                   646-536-7011
    763-315-0013                                jsaunders@theruthgroup.com

SOURCE NeuroVasx, Inc.


'/>"/>
SOURCE NeuroVasx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NeuroVasx Receives CE Mark for cPAX Aneurysm Treatment System
2. NeuroVasx Receives Canadian Approval for cPAX Aneurysm Treatment System
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
Breaking Medicine Technology: